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Abstract
Aims: Sacral neuromodulation (SNM) is a guideline‐recommended treatment
for voiding dysfunction including urgency, urge incontinence, and
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Axonics Modulation Technologies nonobstructive retention as well as fecal incontinence. The Axonics® System is a
miniaturized, rechargeable SNM system designed to provide therapy for at least
15 years, which is expected to significantly reduce revision surgeries as it will not
require replacement as frequently as the non‐rechargeable SNM system. The
ARTISAN‐SNM study is a pivotal study designed to treat patients with urinary
urgency incontinence (UUI). Clinical results at 1‐year are presented.
Methods: A total of 129 eligible UUI patients were treated. All participants were
implanted with a quadripolar tined lead and neurostimulator in a single proce-
dure. Efficacy data were collected using a 3‐day bladder diary, a validated quality
of life questionnaire (ICIQ‐OABqol), and a participant satisfaction questionnaire.
Therapy responders were defined as participants with ≥50% reduction in UUI
episodes compared to baseline. Data were analyzed on all 129 participants.
Results: At 1 year, 89% of the participants were therapy responders. The
average UUI episodes per day reduced from 5.6 ± 0.3 at baseline to 1.4 ± 0.2.
Participants experienced an overall clinically meaningful improvement of
34 points on the ICIQ‐OABqol questionnaire. All study participants (100%)
were able to recharge their device at 1 year, and 96% of participants reported
that the frequency and duration of recharging was acceptable. There were no
serious device‐related adverse events.
Conclusions: The Axonics System is safe and effective at 1 year, with 89% of
participants experiencing clinically and statistically significant improvements
in UUI symptoms.
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urgency incontinence
1 | INTRODUCTION
The Axonics System® provides sacral neuromodulation
(SNM) therapy for the treatment of overactive bladder,
nonobstructive urinary retention, and fecal incontinence.
With an approved functional life of at least 15 years,
the Axonics System is the first rechargeable SNM system
available for use in the United States (Figure 1). The Axonics
System is designed to last approximately three times longer
than the non‐rechargeable SNM system, which needs surgi-
cal replacements at the end of battery life.1 The prolonged
battery life and reduced number of device replacements with
the Axonics System is expected to offer significant ad-
vantages to patients, physicians, and the healthcare system
by reducing surgical risks while providing significant cost
savings.2
In addition, the Axonics System is approved for full‐
body magnetic resonance imaging (MRI) scans. Histori-
cally, patients needing MRI of the body either declined or
were not offered SNM therapy and existing SNM patients
needing MRI of the body had to have the device
surgically explanted or forgo this important diagnostic
tool.3 In addition to the long‐lived nature of this device,
full‐body MRI conditional safety is a significant benefit
for this patient population.
The ARTISAN‐SNM study is a single‐arm, prospective,
multi‐center, pivotal study that was designed to evaluate the
safety and efficacy of the Axonics System for the treatment of
urinary urgency incontinence (UUI). Six‐month results
showed a favorable safety and efficacy profile for the Axonics
System as well as clinically meaningful improvements in
quality of life (QoL).4 This manuscript reports results at
1‐year follow‐up.
2 | METHODS
The ARTISAN‐SNM study protocol was approved by
Ethics Committees at all study sites, and all study parti-
cipants gave informed consent before study enrollment.
Detailed study methods have been previously published4
(ClinicalTrials.gov #NCT03327948).
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All eligible participants were implanted with the
Axonics neurostimulator and quadripolar tined lead in a
single procedure. Fluoroscopic guidance was used to
implant the tined lead along the S3 (preferred) or S4
sacral nerve root following SNM best practices published
by the International Continence Society (ICS).5 A positive
response on a minimum of two electrodes at less than
4mA was required to proceed with full implant, and
none of the study participants undergoing the surgery
failed this criterion. Patients were programmed to the
optimal settings primarily based on intraoperative motor
responses and postoperative sensory responses.
Postoperatively, participants were instructed to
charge their device every 1 to 2 weeks after implant. This
was accomplished using a wireless charging device that is
placed on the skin over the implanted neurostimulator
and held in place using a belt. The recharging process has
been detailed previously,4,6 and details on ease of use and
acceptability of the charging experience are reported in
the Results section.
Efficacy data were collected using a consecutive
3‐day voiding diary, health‐related quality of life
(QoL) questionnaire (ICIQ‐OABqol), and a participant
satisfaction questionnaire. Bowel symptoms, specifi-
cally targeting accidental bowel leakage, were also
captured using the Cleveland Clinic Florida Fecal
Incontinence Score (CCF‐FIS). All adverse events
(AEs) were tracked, analyzed, and reviewed by a data
safety monitoring board.
Participants were considered therapy responders if
they had a ≥50% reduction in UUI episodes on their
voiding diary at follow‐up compared to baseline. The
primary efficacy outcome is the therapy responder rate
for all implanted participants (as‐treated group). Partici-
pants with missing data at follow‐up visits were con-
servatively assumed to be therapy nonresponders.
Analyses were also performed in the “Test Responders”
cohort, defined as participants who were therapy
responders at 1 month. These analyses are performed to
allow comparison with the current clinical literature,
where efficacy results are typically reported only for those
participants that have a positive clinical response during
an external trial period.
In addition to the therapy responder rate analyses,
data analyses included the absolute change and percent
change for the number of UUI episodes, the number of
large UUI episodes, outcomes of the QoL questionnaire,
and participant satisfaction questionnaire results. All
efficacy results for urinary incontinence are assessed
using urge incontinence episodes only. A conservative
approach was taken to analyze missing or exited parti-
cipants as therapy failures for measures on the diary,
QoL, and satisfaction. Recharging experience is reported
based on available data (ie, excludes missing or exited
participants).
3 | RESULTS
3.1 | Study participants
A total of 129 participants met the IE criteria and were
implanted with the Axonics System in a single procedure.
There were no intraoperative test failures. The average
age of participants was 59.3 years old (21‐86 years) and
98% were female. At baseline, participants had 5.6 ± 0.3
(average ± standard error) UUI episodes per day.
Detailed demographics and baseline characteristics are
shown in Table S1.
Over 96% of the participants (124 of 129) completed
the 1‐year visit. Five participants, including three Test
Responders, exited before the 1‐year visit (details in
Safety section). An as‐treated analysis was performed
for symptom‐specific measures, where participants
FIGURE 2 Therapy responder rates in all implanted
participants at different follow‐up visits post‐implant. UUI therapy
response is defined as ≥50% reduction in UUI episodes at follow‐up
as compared to baseline. As‐treated analysis is presented, where
explanted or exited participants are considered as treatment
failures. UUI, urinary urgency incontinence
FIGURE 1 The FDA‐approved Axonics System includes a
rechargeable, miniaturized implantable neurostimulator that is
~5cc in volume and has a 15‐year approved life in United States,
Europe, Canada, and Australia. In addition, the Axonics System
is conditionally approved for full‐body MRI scans at 1.5 and 3T
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unavailable at follow‐up are considered treatment
failures.
3.2 | Therapy responder rate and UUI
symptom reduction
Eighty‐nine percent of the study participants (115 of 129)
were therapy responders at 1 year (ie, had ≥50%
reduction in UUI symptoms as compared to baseline;
Figure 2A). Of the 129 participants, 113 (88%) were Test
Responders at 1‐month. Of the Test Responders, 94%
(106 of 113) were therapy responders at the 1‐year follow‐
up. A consistent responder rate was seen from 1‐month to
1‐year visits, showing sustained efficacy of the therapy.
In all implanted participants (n = 129), the average
UUI episodes per day reduced from 5.6 ± 0.3 at baseline
to 1.4 ± 0.2 at 1 year (P< .0001), which represents a 75%
reduction in UUI episodes (Figure 3A). Seventy‐seven
percent of the therapy responders (88 of 115) had a
greater than 75% reduction in UUI episodes, including
29% of responders that were completely dry (achieved
complete urinary continence) (Figure 3B).
Eighty‐one study participants had at least one large
leak per day at baseline as reported on the 3‐day bladder
diary. In this group, the average large leaks per day
reduced from 1.6 ± 0.2 at baseline to 0.2 ± 0.1 at 1 year
(P< .0001), which represents an 87.5% reduction in large
leak episodes. Seventy four percent of the participants
with large leaks at baseline (60 of 81) had a 100%
reduction in the large leak episodes, and 83% had ≥75%
reduction in large leak episodes.
3.3 | Quality of life and therapy
satisfaction
At 1 year, study participants averaged a 34.4‐point im-
provement on the health‐related quality of life (HRQL)
measure of the ICIQ‐OABqol questionnaire (P< .0001),
a clinically meaningful improvement as compared to
baseline7 (Figure 4). Improvements in QoL were seen on
FIGURE 3 Symptom reduction in all implanted participants (n = 129) at 3 months, 6 months, and 1 year. A, Average number of UUI
episodes in all implanted participants at baseline, 3 months, 6 months and 1 year. B, Magnitude of UUI episode reduction in therapy responders
(n= 115) at 1‐year follow‐up. Error bars represent standard error. *P< .0001 compared to baseline. UUI, urinary urgency incontinence
FIGURE 4 Quality of life scores in all implanted participants as assessed by ICIQ‐OABqol in an as‐treated analysis. Health‐related QoL
(HRQL) composite score and all subscale scores show clinically and statistically significant improvements compared to baseline (P< .0001
for all comparisons, n = 129). Error bars represent standard error. All scores exceeded the minimally important difference of 10 points,
which is the minimally important difference typically considered clinically meaningful to patients7 for improvement in QoL
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all domains of the ICIQ‐OABqol subscales, with im-
provements of 39.3 points on Concern, 38.6 points on
Coping, 32.6 points on Sleep, and 22.4 points on Social
Interaction.
In addition, 93% of the 129 participants responded as
being “satisfied” with their rechargeable SNM therapy,
and 92% responded that they would undergo the therapy
again (Figure 5A).
3.4 | Recharging experience
At 1 year, 100% of participants reported being able to
recharge their system, and 89% of participants found it
“easy” to recharge the system (Figure 5B).
At 1 year, 86% of participants (107 of 124) reported
recharging their system for less than 1 hour, and 95%
of participants reported going at least 7 days between
recharging sessions. The duration and frequency of
recharging was reported as “acceptable” by 96% of
participants (Figure 5B).
3.5 | Additional outcome measures:
urgency, urgency frequency, and fecal
incontinence
Study participants also experienced reductions in
overall urgency episodes (ie, urgent voids and/or
leaks), urgency frequency, and fecal incontinence
symptoms. At baseline, participants had 10.6 ± 0.3
urgency episodes per day which reduced to 7.4 ± 0.3 at
1 year (P < .0001).
Of the 129 participants, 103 had urinary frequency
defined as ≥8 voids per day. These participants averaged
11.6 ± 0.3 voids per day at baseline, which reduced to
8.9 ± 0.2 voids per day at the 1‐year follow‐up (P< .0001).
Of the 129 participants, 42 (33%) had fecal incon-
tinence at baseline, as determined by a score of 6 or
greater on CCF‐FIS.8 The average CCF‐FIS score at
baseline was 9.3 ± 0.5 and was reduced to 3.9 ± 0.6 at 1
year (Figure S1A; P< .0001). In addition, at 1 year 55
participants self‐identified and reported their level of
satisfaction with therapy for their fecal incontinence
symptoms. Ninety‐one percent of these participants
(50 of 55 participants) reported being satisfied with the
SNM therapy for their bowel symptoms (Figure S1B).
3.6 | Safety
A total of 15 device‐related AEs were reported across
14 participants (10.8% of participants) at 1 year, with 10
AEs being reported before the 6‐month follow‐up. The
most frequent AE was discomfort due to stimulation,
which accounted for seven events in seven (5.4%)
participants, all of which were resolved with repro-
gramming. One patient (0.8%) experienced some dis-
comfort/heating near the charging area, which was
resolved by retraining the patient on a proper charging
technique.
Two events of pain at the neurostimulator site (1.6%)
occurred, both of which resolved spontaneously. Two
lead revisions were performed in two patients, one for a
lead migration (0.8%) and another for high impedances
(and suspected lead fracture, 0.8%). The lead revisions
resulted in the successful return of efficacy in both
patients.
A total of five participants exited before 1 year; three
of whom exited before the 6‐months visit. Reasons for
FIGURE 5 Participant satisfaction with therapy and recharging experience at 1 year. A, Participant satisfaction with SNM therapy and
likeliness of undergoing therapy again for the same outcome. The as‐treated analysis is performed in all implanted participants (n = 129),
with missing participants conservatively considered as having negative responses. B, Ease of charging and acceptability of charging duration
and frequency. Analyses performed in available participants at 1 year (n = 124). SNM, sacral neuromodulation
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participant study exit were system explant in four parti-
cipants (1 infection, 1 pain unrelated to the device,
2 insufficient efficacy), and death unrelated to study
device or procedure in one participant.
4 | DISCUSSION
This study represents the 1‐year safety and efficacy out-
comes of the Axonics System for the treatment of UUI.
The consistency of the results out to 1‐year supports the
durability of the therapy as well as an excellent safety
profile. The as‐treated 89% therapy response rate at 1 year
is one of the highest reported in the literature and was
calculated using the most conservative methodology. In
addition, the magnitude of the therapy response, with
29% of participants being dry and 77% achieving
≥75% improvement, far exceeds the traditional definition
of success at 50% improvement. The ARTISAN‐SNM
therapy response rate was calculated in all implanted
participants, including the initial therapy failures and
participants that exited the study. This contrasts with the
InSite study where the therapy response rate was eval-
uated in only participants available for evaluation at
follow‐up and excluded participants who were initial
therapy failures and participants who exited the study.
As reported previously,4 we hypothesize that several
factors may contribute to the high therapy responder
rate. A recent study by Adelstein et al9 (2019) showed
that high trial success rates (88%) can be achieved by
optimal lead placement which includes the use of the
curved stylet. The adoption of best practice techni-
ques5,10,11 for optimal lead placement undoubtedly con-
tributed to the success in this study as evidenced by the
88% responder rate at 1 month. The durability of the
response from 1 month to 1 year may also be attributed in
part to the additional features of the rechargeable system,
including the use of constant current stimulation and the
easy to use, intuitive patient remote control. Future
comparative studies are needed to evaluate the specific
contribution of these additional factors on short‐term and
long‐term efficacy.
Although this study was not designed to evaluate the
efficacy of the Axonics System in patients with fecal in-
continence, 1/3 of the study cohort reported suffering
from this condition. Based on our questionnaire data,
participants had a reduction in the CCF‐FIS from 9.3 at
baseline down to 3.9 at 1‐year. Recent data suggest that a
reduction to a score <9 correlates to an important im-
provement in patients’ quality of life.8
The Axonics System is the first rechargeable SNM
system with an approved device life of 15 years or longer.
The long life of the Axonics System is made possible by
its rechargeable battery. Patient recharging experience
with the Axonics System has been very encouraging. At
1 year, all study participants were able to recharge their
system, and the vast majority (89%) reported it was easy
to recharge the system and 96% reported recharging
frequency and duration was acceptable. These results are
consistent with the literature for rechargeable spinal cord
and deep brain stimulation systems which have shown
high satisfaction, including 85% to 90% of patients
preferring or recommending rechargeable devices.12‐14
At 1 year, the safety profile of the ARTISAN‐SNM
study remained excellent. There have been no un-
anticipated or serious device or procedure‐related AEs.
Most of the device‐related AEs occurred within the first
6 months (63%), with only 37% of AEs occurring between
6 and 12 months. As previously reported, there was a
<1% infection rate which is one of the lowest reported in
the SNM literature. The low infection rate may be attri-
butable to the protocol requirements designed for infec-
tion prevention4 and smaller pocket size. A notable
aspect of the safety results of this study is that there have
been no surgical interventions for pain at the neuro-
stimulator site. This contrasts with the Medtronic InSite
study where 7% of participants reported pain at their
neurostimulator site, of which 50% had to undergo sur-
gical revision or explant. In the ARTISAN‐SNM study,
the overall surgical intervention rate remained low at six
participants (4.6%), two of which were initial non-
responders that were explanted due to continued lack of
efficacy. The 1‐year safety data for the Axonics System is
reassuring and consistent with other reports of the
safety of SNM.
Having a safe and effective treatment option for pa-
tients suffering from UUI and OAB is important given
the recent JAMA article linking the risk of dementia
and exposure to anticholinergic medications.15 The arti-
cle adds to a growing body of evidence highlighting the
importance of reducing exposure to anticholinergic drugs
especially in middle‐age and older adults, which corre-
lates to the population of OAB/UUI sufferers. A long‐
lived, rechargeable SNM system provides a safe and
effective alternative to using anticholinergics for the
treatment of OAB/UUI.
The strengths of this study include the conservative
data analysis methods, which provide an objective and
robust measure of therapy response in all patients trea-
ted. In addition, the collection of recharging usability
data provides insight into the patient charging experi-
ence, showing high participant satisfaction. Study lim-
itations include that this was a nonrandomized study,
with no comparator or placebo arm. However, given that
SNM is a widely accepted treatment with well‐known
efficacy, the use of a placebo was considered unnecessary.
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In addition, the majority of the study participants were
female, potentially limiting the generalizability of the
findings. However, given that UUI/OAB is more pre-
valent in female participants than males,16,17 this was
expected. It should also be noted that another study with
the same device (RELAX‐OAB) had a higher percentage
of males (25%) and showed that the therapy worked
equally well for the male population.18
5 | CONCLUSION
The ARTISAN‐SNM study demonstrates that the Axonics
System provides sustained, long‐term, safe and effica-
cious outcomes in patients with urgency urinary incon-
tinence. At 1‐year post‐implant, clinically meaningful
improvements in patient quality of life and high rates
of satisfaction with the therapy and the recharging
experience were achieved.
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